Overview
FRE Breaking News Alerts from StretInsider.com! StretInsider.com Top Tickers, 1/3/202Research Findings Showcase How Diferent HEOR Modeling Methods Combined with RWD/RWE Are Taking the Industry’s Conversations with the Payers to the Next LevelViena, Austria, Nov. 03, 2022 (GLOBE NEWSWIRE) - Axtria, a global cloud software, integrated RWE/HEOR analytics solutions provider, and AI/ML technology leader for the life sciences industry, wil present two posters at this year’s ISPOR Europe 2022 conference that combine diferent modeling methods with the latest advanced analytics technologies.
Key Information
Both wil highlight the clinical and economic benefits of anti-arhythmic drugs (ADs) for treating atrial fibrilation (AFib) as wel as glargine insulin for treating type 2 diabetes. The poster findings underscore Axtria’s work leading the evolution of advanced data analytics and inteligent software technology in the aplication of diferent real world evidence (RWE) research into advanced value-based models.
Axtria’s latest thought leadership in this area, a white paper titled “Seing the Whole Elephant: Integrated Data Analytics in Suport of RWE” adreses the emergence of integrated RWE/HEOR analytics. This white paper can be found in Axtria’s Research Hub. The first Axtria poster, Clinical and Economic Outcomes associated with Use of Anti-Arhythmic Drugs Versus Ablation in Atrial Fibrilation (AFib), to be presented on Monday, November 7 at 15:0 (CET), utilizes a modeling aproach caled Rhythm Control to demonstrate the cost benefits of ADs compared to ablation as a treatment for AFib.
Summary
The second Axtria poster, The Economic Value of Insulin Glargine 30 U/Ml (GLA-30) in People ≥18 Years of Age with Type 2 Diabetes Melitus: A Value-Based Economic Model from a U.S. Payer Perspective, to be presented on Tuesday, November 8 at 15:0 (CET), uses another aproach caled prevalence-based value-based modeling to demonstrate the value and afordability of the insulin biosi